We combine deep proteomics with machine learning to better combat complex diseases and create a healthier world.
.png)
.png)
.png)
To open the bottlenecks of discovery, we rely on the talent intersection of cutting-edge biology, proteomics, powerful software, and machine learning capabilities. This has been our compass for building our company from day one.
Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.
Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.
Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.
Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.
Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.
Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.
Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.
Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.
Prof. Bradley Monk from the department of Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona, is an established clinical trialist, drug developer and translational scientist in gynecologic cancers. He has authored and co-authored hundreds of peer reviewed publications, and has focused his research on gynecologic surgery-complex, cervical cancer, ovarian cancer, and other gynecologic cancers.
Prof. Bradley Monk from the department of Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona, is an established clinical trialist, drug developer and translational scientist in gynecologic cancers. He has authored and co-authored hundreds of peer reviewed publications, and has focused his research on gynecologic surgery-complex, cervical cancer, ovarian cancer, and other gynecologic cancers.
Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.
Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.
Prof. Ma’ayan is a Mount Sinai Endowed Professor in Bioinformatics, Professor in the Department of Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics. The Ma'ayan Laboratory develops computational tools to study the complexity of regulatory networks in mammalian cells. Professor Ma’ayan lab is one of the world leading groups in ML driven tools and analysis for proteomics and post-translational-modification data for translational research.
Prof. Ma’ayan is a Mount Sinai Endowed Professor in Bioinformatics, Professor in the Department of Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics. The Ma'ayan Laboratory develops computational tools to study the complexity of regulatory networks in mammalian cells. Professor Ma’ayan lab is one of the world leading groups in ML driven tools and analysis for proteomics and post-translational-modification data for translational research.
Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide
Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide
Get in touch with us for questions and potential collaborations.
